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This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
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Abstract   
 
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a rare but serious and 
potentially fatal clinical condition.  Recent reports have suggested a possible association with the 
development of PPHN in the neonate, to mothers who have been exposed in the later stages of 
pregnancy to selective serotonin re-uptake inhibitors (SSRI), an antidepressant medication. This 
review will investigate the most recent literature to determine the prevalence of PPHN among mothers 
exposed to SSRIs in late pregnancy. 
Methods: A systematic review of the literature published in the previous five years was conducted on 
the MEDLINE, CINAHL, and ISI World of Science databases using the keywords PPHN, SSRI, and 
pregnancy.  Articles that examined outcomes of PPHN with SSRI exposure in pregnancy after 20 
gestational weeks were selected.  Research that focused on antidepressant use other than SSRIs or 
outcomes with early exposure during pregnancy was excluded.   
Results: Three articles that investigated the effects of SSRI exposure in late pregnancy and PPHN 
were analyzed for significant results.  Two of the three articles agreed that there is an almost six fold 
increase in PPHN in infants exposed to SSRIs later in pregnancy.  One study found no significant 
difference in the prevalence of PPHN and SSRI use in the third trimester of pregnancy.   
Conclusion: The data reviewed suggests that there is a possible connection with SSRI exposure in late 
pregnancy and the development of PPHN in infants.  However, the data at this time are limited and not 
conclusive.  The information gathered in this systematic review should be considered in the decision to 
initiate, continue, or discontinue an SSRI during pregnancy. 
Keywords: PPHN, SSRI, pregnancy   
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Selective Seratonin Re-uptake Inhibitors (SSRIs) Exposure in Late Pregnancy and Incidence of 
Persistent Pulmonary Hypertension of the Newborn (PPHN) 
 
 
BACKGROUND 
Overview 
Persistent pulmonary hypertension of the newborn (PPHN) is a rare but serious and sometimes 
fatal neonatal complication.  PPHN is a condition characterized when the pulmonary vasculature fails 
to relax after birth, leading to a decrease in pulmonary blood flow and shunting of unoxygenated blood 
to the systemic circulation.1, 2  PPHN occurs in an estimated 1-2 per 1000 live births and is more 
commonly found in full-term or near-term infants than pre-term infants.2 
A number of clinical conditions, including meconium aspiration syndrome, pneumonia, sepsis, 
respiratory distress syndrome, non-vertex presentation, post maturity, maternal diabetes, and cesarean 
section, are associated with PPHN.2, 3 Possible physiological mechanisms leading to the development 
of PPHN include decreased production or responsiveness to vasodilators such as nitric oxide; increased 
production or responsiveness to vasoconstrictors such as endothelin; or changes in production or 
responsiveness to both vasodilators and vasoconstrictors.4 On pathological study, infants with PPHN 
are found to have congenital pulmonary vascular remodeling involving increased muscularization of 
the pulmonary arterioles.5 
These findings suggest that prenatal exposures can contribute to the pathogenesis of PPHN.5 
The results of a previous small cohort study conducted by a teratogen-information service generated 
the hypothesis that maternal use of selective serotonin re-uptake inhibitors (SSRIs) in late pregnancy 
may be a risk factor for PPHN.6  Among 174 infants born to women who used a specific SSRI, 
fluoxetine, for some portion of their pregnancies, two of the 73 babies that were exposed to fluoxetine 
up to the time of delivery had PPHN, as compared with zero of the 101 exposed only early in 
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pregnancy.6  Another recent study suggested an association between maternal use of SSRIs and PPHN 
in infants born after 34 gestational weeks.  This study performed by Chambers et al reported a six-fold 
increase risk of PPHN associated with maternal use of SSRIs in late pregnancy.5  
The research done by Chambers et al is significant due to the substantial increase over the last 
10 years in SSRI use during pregnancy.7 Approximately 4 million live births occur in the United States 
each year, and about 92 000 of these infants are prenatally exposed to SSRIs.8  SSRIs are the first-line 
pharmacotherapy for depression, and amounts for 77.5% of antidepressant use during pregnancy.8 
According to one report almost three percent of all infants have been exposed to SSRIs through the end 
of pregnancy.8  Since Chambers et al was published in 2006, other studies7, 9, 10 have been performed 
testing the validity of their results.   
 
Purpose of Study 
The purpose of this work is to systematically review the most recent clinical research in the use 
of SSRIs during late pregnancy and the reported increased correlation of neonates developing PPHN.  
Expectant mothers are required to make decisions that impact both maternal and fetal health.  Pregnant 
women faced with this situation must balance the most accurate information available with their 
particular circumstances to aide them in making the most correct decision. 
 
METHODS 
Search Strategies 
 A search of the literature published in the previous five years was conducted on the 
MEDLINE, CINAHL, and ISI World of Science databases using the following search terms: PPHN, 
SSRI, pregnancy. Subsidiary MeSH terms were selected where appropriate and permitted by the search 
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engine (i.e.- “persistent fetal circulation of the newborn” to PPHN). Consequently an examination of 
bibliographic entries in retrieved works provided additional sources for consideration. 
This systematic review analyzed information from studies that contribute to the understanding 
of SSRI use in late pregnancy and particularly to its possible association with PPHN.  Only studies 
published in the last five years with emphasis on continued or onset SSRI exposure after 20 weeks 
gestation to those with no exposure and outcomes of babies born after 34 weeks gestation were 
reviewed. Retrospective cohort and case-controlled studies were included.  No randomized control 
trials were found in relation to this topic. 
 
Inclusions/Exclusions 
The search was limited to English language publications, expectant mothers, and neonatal 
outcomes.  Articles that focused on antidepressants other than SSRIs, SSRIs used in early pregnancy 
and discontinued, depression in pregnancy or neonatal outcomes other than PPHN were excluded.   
A relative score representing quality and validity was then given to each article using an 
original process (see Table 1).  Higher scores were awarded to those studies with large population 
sizes, prospective exposure information, and quality of methods used to acquire information.  Lower 
scores were awarded to studies with small population sizes, use of retrospective maternal interviews, 
and inability to satisfactorily reduce confounding factors.  Studies were not included or excluded based 
solely on their score. 
 
RESULTS 
After these exclusions, three articles professed to compare SSRI use in late pregnancy and 
PPHN (see Table 2).  These articles reviewed for the purpose of this work specifically assessed the 
possible relationship between SSRI exposure in late pregnancy and PPHN in neonates born after 34 
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weeks gestation.  Chambers et al5 performed a follow up study after the authors’ previous article 
generated the hypothesis that maternal use of SSRIs in late pregnancy may be a risk factor for PPHN.5, 
6 However, the result of this study has lead other researchers to conduct their own independent studies 
in order to authenticate the observation of a potential connection between SSRI exposure in late 
pregnancy and PPHN.   
A retrospective case control study performed by Chambers et al in 2006, published in The New 
England Journal of Medicine, enrolled 637 infants with possible PPHN.  The diagnosis was then 
confirmed in 377 of the infants after certain inclusion/exclusion criteria were met upon review of the 
medical records.  These 377 patients were then matched with 836 control patients that did not have 
exposure to SSRIs.  The control group consisted of infants born after 34 weeks gestation without 
malformations who were matched with patients according to the hospital in which they were born and 
their date of birth (+/- 30 days).  Within six months of delivery, trained nurses, unaware of the study 
hypothesis, performed telephone interviews with the mothers in both the control and study groups.5  
Chambers et al reported that the crude risk of PPHN associated with the use of any 
antidepressant at any time in pregnancy was not significantly elevated (odds ratio (OR), 1.3; 95% 
confidence interval (CI), 0.7 to 2.2), nor was the use of SSRIs alone at any time in pregnancy 
significantly associated with PPHN (OR, 1.5; 95% CI, 0.8 to 2.9).  However, when the comparison 
was stratified according to the timing of exposure in pregnancy, use of any antidepressant after the 20th 
week of gestation was significantly associated with PPHN (OR, 2.9; 95% CI, 1.3 to 6.5).  Further 
analysis demonstrated that this association was entirely attributable to the subgroup of infants with late 
exposure to SSRIs (OR for SSRI use after 20th week of gestation relative to no use in the pregnancy, 
5.1; 95% CI, 1.9 to 13.3).  There was no increased risk of PPHN when SSRI use was restricted to the 
first half of the pregnancy (OR, 0.3; 95% CI, 0.1 to 1.1).5  
Further analysis showed that 12 of the 14 mothers with late SSRI exposure whose infants had 
PPHN continued use of their medication into at least the eighth month of pregnancy.  Post hoc analysis 
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using a cutoff point of 26 weeks gestation yielded identical results (adjusted odds ratio, 6.1; 95 percent 
confidence interval, 2.2 to 16.8).5 
In contrast another retrospective case control study performed by Andrade et al published in 
Pharmacoepidemiology and Drug Safety in 2009 found no association between SSRI use in late 
pregnancy and PPHN.  The authors randomly matched 1104 patients who were not exposed to 
antidepressants with 1104 women who had received an antidepressant in the third trimester.  The vast 
majority of women whose infants were included in the exposed group (85%) received an SSRI in the 
third trimester.  This study used automated pharmacy records to identify medication exposures.  The 
researchers then reviewed medical charts from 1 January 1996 to 31 December 2000 using expert 
reviewers looking for inpatient diagnosis or procedure codes of interest with PPHN.  A total of five 
cases of PPHN were classified by the expert reviewers as having ‘possible’ PPHN.  Two of the cases 
were among infants exposed to antidepressants in the third trimester and three were among infants 
unexposed to antidepressants.  The two exposed cases were exposed to SSRIs in all trimesters of 
pregnancy.7 
The prevalence of PPHN among infants whose mothers were exposed to any antidepressant in 
the third trimester was 1.81 per 1000 infants (95% CI 0.22, 6.54) overall.  Among those infants whose 
mothers were exposed to SSRIs in the third trimester, the prevalence was 2.14 per 1000 (95% CI 0.26, 
7.74), while the prevalence of PPHN among infants whose mothers were not exposed to 
antidepressants was 2.72 per 1000 (95% CI 0.56, 7.93).  The prevalence ratio for the association 
between PPHN and antidepressant use was 0.67 (95% CI 0.06, 5.82).  The data generated from this 
study was unable to find an increased risk of PPHN with maternal use of SSRIs in the third trimester.7 
Swedish researchers Källén and Olausson gathered information from the Swedish Medical 
Birth Register for the years 1997-2005.  Practically all Swedish women who give birth have attended 
the free maternal health service and make their first visit usually before gestational week 12.  At this 
visit, the women are interviewed by a midwife and the answers are recorded in a standardized form, 
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used all over Sweden.  Infants born to women who had used SSRI drugs during pregnancy in 1997-
2005 were studied and compared with all other infants recorded in the Medical Birth Register (n= 831 
324). Identification of infants with PPHN was made from neonatal diagnoses, coded in the modified 
ICD-10 (International Statistical Classification of Diseases and Related Health Problems) code P293B 
which specifies PPHN and has been used in Sweden since 1997 when ICD-10 was introduced.9  
A total of 506 infants were identified with a discharge diagnosis of PPHN among the  
831 324 born.  When all cases were analyzed, an increased risk for PPHN was seen among the SSRI-
exposed infants.  The risk was slightly higher when the analysis was restricted to infants who had been 
exposed to SSRI in late pregnancy when compared with early pregnancy (Risk ratio (RR) 2.91; 95% 
CI, 0.94 to 6.78 with late exposure vs. RR, 2.01; 95% CI, 1.00 to 3.60 with early exposure).  When the 
analysis was made on infants exposed in late pregnancy, slightly higher risk estimates were seen, 
statistically significant when the analysis was restricted to infants born after 34 completed gestational 
weeks (RR, 3.57; CI, 95% 1.16 to 8.33 late exposure vs. RR, 2.38; CI, 95% 1.19 to 4.25 early 
exposure).9 
 
DISCUSSION 
Review 
After careful investigation of the recent literature on the topic, there remain conflicting answers 
about the risk of SSRI use in late pregnancy and its association with PPHN.  Of the three articles 
assessed for the purpose of this review Chambers et al and Källén and Olausson agreed that there 
appears to be an increased risk with exposure of SSRIs in late pregnancy and PPHN.5, 9 The study 
performed by Andrade et al was unable to find any increased risk.7  Källén and Olausson’s work was 
unique in that although it was retrospective in nature it had an advantage that the exposure information 
was prospective and not based on retrospective inquiries.9  Overall the studies5, 9 that agreed on the 
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increased risk associated with SSRI use and PPHN were more complete and thorough than Andrade et 
al.  Both Chambers et al and Källén and Olausson had a larger population of children with PPHN to 
study.  They were able to limit their confounders, and their inclusion criteria were more precise than 
that of Andrade et al.   
   
Study Limitations 
The articles selected for review demonstrate different research methods and accordingly vary in 
their quality.  Investigating the potential effect of a certain class of medication on pregnant women and 
unborn children has ethical considerations that prevent randomized control trials and therefore 
information on the specific topic is necessarily limited.  Therefore, retrospective population, cohort, 
and case-control matched studies supply the totality of information available on the subject.   
Both Chambers et al and Andrade et al searched medical records for information to identify 
potential cases based on certain diagnostic criteria.5, 7 Although both studies were published recently, 
2006 and 2009 respectively, during the study period chosen by the authors, no specific ICD-9 code was 
available for documentation of PPHN.5, 7  This means that researches were forced to rely on an 
extensive search through admission/discharge records, complicated medical charts both neonatal and 
maternal, and neonatal intensive care logbooks to extrapolate specific information regarding 
depression, SSRI use, and PPHN that would meet each authors detailed criteria for inclusion into the 
study.5, 7 This exhaustive search through complicated data suggests that some cases of PPHN may have 
been undetected in the study population.7  Andrade et al also note in their paper that the length of 
gestation was not available in the administrative databases and therefore they assumed a 270 day 
gestational period.7  Although their study intended to include only full-term or near-term infants (>34 
weeks gestation) their assumption may have permitted some pre-term infants into their results.7  The 
use of maternal interviews performed up to six months after delivery by Chambers et al introduces the 
notion of recall bias into their results.  
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Given that PPHN is a rare condition in the general population it is difficult to design a study 
with an extremely large number of babies that are affected by PPHN.  Andrade et al had only five 
cases of PPHN out of 2208 enrolled in their study.  Chambers et al had 637 infants with possible 
PPHN but could only confirm 377 cases.  Källén and Olausson needed over 830 000 babies born to 
find 506 infants with PPHN.  This natural limitation restricts the amount of research that can be done 
with the relationship between SSRIs and PPHN. 
 
Confounders 
Confounding variables are another important concept in the analysis of all the reviewed 
articles.  As previously mentioned there are many clinical conditions and physiological mechanisms 
associated with PPHN.  Other maternal risk factors provide many of the confounding factors such as 
lower educational level, maternal age, parity, body mass index (BMI), smoking, alcohol use, use of 
nonsteroidal anti-inflammatory agents (NSAIDS), caesarian section, and diabetes were noted.2, 3  
However, information on the confounding variables was limited because the clinical question was 
simply based on exposure to SSRIs and development of PPHN.  Only Källén and Olausson made 
seperate analytical adjustments for four possible confounders (maternal age, parity, smoking and 
BMI). 
All articles reviewed in this present study were simply assessing the exposure of SSRI use in 
late pregnancy and relationship with PPHN.  None of the studies differentiated between different 
dosages, treatment regimens, and severity of depression among those in the exposed group. 
 
CONCLUSION 
After careful review of the articles mentioned in this study, there appears to be an increased 
risk between SSRI use in late pregnancy and PPHN.  However, the data on the subject at this time is 
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limited and is not by any means conclusive.  It should be noted that PPHN is a rare medical condition.  
Assuming that there is a six fold increase in the risk of SSRI use and PPHN as previously reported,5 
the risk of having a baby with PPHN among those who use SSRIs late in pregnancy is still relatively 
low (about 6-12 per 1000).  In other words, even assuming a six fold increased risk, about 99% of 
women exposed to SSRIs late in pregnancy will deliver an infant unaffected by PPHN.  Despite the 
rarity of PPHN due to the increasing number of women who will be treated with SSRIs in their 
pregnancy the potential risks and benefits must be carefully considered.  Further research will enable 
both the clinician and patient to make a more balanced assessment when confronted with the decision 
to safely initiate, continue, or discontinue an SSRI during pregnancy.  
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Table 1: VRASS 
Criterion Score +1 Score 0 
Sample size Greater than 100 babies 
with PPHN in study 
Less than 100 babies with 
PPHN in study  
Information Gathering 
Method 
Use of large conformed 
databases. 
Prospective exposure 
information 
Search of medical records 
for possible potential cases. 
Use of maternal interviews. 
Evident and Accurate 
Results 
Clear and concise 
explanation of results with 
data sets or tables. 
Minimal study limitations 
Hidden information and 
inability to minimize study 
limititations. 
Study Limited Exposure to 
Late Pregnancy 
Exposure after 20 weeks 
gestation 
Exposure at any time during 
pregnancy, but results 
separated into early and late 
exposure. 
Inclusion/Exclusion Criteria Use of precise coding 
specifically for PPHN 
Based on interpretation of 
medical records and clinical 
opinions. 
 
Table 2: Reviewed Articles Matrix 
Study/Design Population Comparison  Outcome RP-TASS Score (of 
5)/Comments 
Chambers et al 
(2006) 
Retrospective 
case-control 
1213 Women and 
infants 
 377 babies with 
PPHN 
SSRI in late 
pregnancy vs. no 
SSRI 
Babies with 
PPHN 
3/5. Use of maternal 
interviews. Initial study 
on clinical question 
Andrade et al 
(2009) 
Retrospective 
case-control 
2208 women and 
infants 
5 babies with 
PPHN 
SSRI in 3rd 
trimester of 
pregnancy vs. no 
SSRI use 
Babies with 
PPHN 
1/5. Small number of 
babies with PPHN.  
Possibility of inclusion 
of babies not intended in 
study population  
Källén & 
Olaussen (2007) 
Retrospective 
cohort 
831 234 women 
506 babies with 
PPHN 
SSRI use during 
pregnancy vs. no 
SSRI use 
Babies with 
PPHN   
4/5. Use of Swedish 
National Birth Registrar 
for conformed concise 
information gathering. 
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